Stereotaxis (NYSE:STXS) announced today that it submitted its MAGiC catheter for CE mark approval in Europe. The St. Louis-based company designed MAGiC as a robotically navigated, magnetic interventional ablation catheter for minimally invasive cardiac ablation procedures. Used in conjunction with Stereotaxis' robotic systems, the catheter … [Read more...] about Stereotaxis submits robotically navigated ablation catheter for CE mark
Advanced NanoTherapies closes $7.2M Series A for drug-coated balloon
Advanced NanoTherapies announced today that it closed an oversubscribed Series A equity financing round. Los Gatos, California-based Advanced NanoTherapies, which develops the SirPlux Duo drug-coated balloon (DCB) for treating de novo coronary artery disease (CAD) lesions, has now raised $12.5 million in total since September 2020. Get the full … [Read more...] about Advanced NanoTherapies closes $7.2M Series A for drug-coated balloon
Endologix reports positive results from percutaneous bypass trial
Endologix announced today that 12-month results from a trial of its Detour system demonstrated a low rate of complications. Irvine, California-based Endologix's Detour 2 FDA investigational device exemption (IDE) study was designed to evaluate the safety and effectiveness of the Detour system for percutaneous bypass in the treatment of … [Read more...] about Endologix reports positive results from percutaneous bypass trial
FDA approves Medtronic’s In.Pact 018 drug-coated balloon catheter
Medtronic (NYSE:MDT) announced that it received FDA approval for its In.Pact 018 paclitaxel-coated balloon catheter. Fridley, Minnesota–based Medtronic's In.Pact 018 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, a drug-coated balloon product, received an indication for the interventional treatment of peripheral … [Read more...] about FDA approves Medtronic’s In.Pact 018 drug-coated balloon catheter
Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
Data presented today at the EuroPCR 2022 event supported the use of the Medtronic (NYSE:MDT) Resolute Onyx drug-eluting stent. University of Padua Medical School Head of Interventional Cardiology Dr. Giuseppe Tarantini presented late-breaking clinical trial results from the investigator-initiated, Medtronic-funded ROLEX (Revascularization Of … [Read more...] about Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
Medtronic (NYSE:MDT) announced today that it received FDA approval for its Onyx Frontier drug-eluting stent (DES). Onyx Frontier, the latest iteration of Medtronic’s Resolute DES family, was designed to leverage the same stent platform as Resolute with an enhanced delivery system for improving deliverability and increasing acute performance, … [Read more...] about FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
Abbott (NYSE:ABT) announced today that its Xience Skypoint drug-eluting stent platform is now available globally. Xience Skypoint has received FDA approval, CE mark and PMDA approval in Japan for the broadest expansion with the availability of extended sizes of 4.5 mm and 5 mm offerings. Get the full story at our sister site, Drug Delivery … [Read more...] about Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
ICU Medical beats The Street in Q1
ICU Medical (Nasdaq:ICUI) reported first-quarter results that came in ahead of the consensus earnings per share forecast. The San Clemente, California-based company posted losses of $38.1 million, or $1.61 per share, on sales of $543.1 million for the three months ended March 31, 2022, for a bottom-line slide into the red on sales growth of … [Read more...] about ICU Medical beats The Street in Q1
Avanos rises as Q1 earnings match Wall Street projections
Avanos Medical (NYSE:AVNS) shares ticked up today on first-quarter results that just about matched the consensus forecast. The Alpharetta, Georgia–based pain management and chronic care device company posted profits of $5.8 million, or 12¢ per share, on sales of $197.4 million for the three months ended March 31, 2022, for a bottom-line gain … [Read more...] about Avanos rises as Q1 earnings match Wall Street projections
Study demonstrates freedom from AFib symptoms with use of Abbott’s ablation catheter
Abbott (NYSE:ABT) announced today that a study showed its TactiCath ablation catheter often led to more than a year of freedom from AFib symptoms. The Persist-End study showed that 89% of patients treated for persistent AFib with the company’s TactiCath contact force ablation catheter, Sensor Enabled (TactiCath SE), remained symptom-free for up … [Read more...] about Study demonstrates freedom from AFib symptoms with use of Abbott’s ablation catheter